Summary
Signal counts
Assets tracked: 9
Watchlist assets: 5
Registry stop assets: 1
Sponsor overview
Sun Yat-sen University
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT05578287 | https://clinicaltrials.gov/study/NCT07589049 | https://clinicaltrials.gov/study/NCT07518979 | https://clinicaltrials.gov/study/NCT07579598 | https://clinicaltrials.gov/study/NCT07649980 | https://clinicaltrials.gov/study/NCT03245905 | https://clinicaltrials.gov/study/NCT05113355 | https://clinicaltrials.gov/study/NCT02986451 | https://clinicaltrials.gov/study/NCT06957561 | https://clinicaltrials.gov/study/NCT03668730 | https://clinicaltrials.gov/study/NCT07489703 | https://clinicaltrials.gov/study/NCT05988372 | https://clinicaltrials.gov/study/NCT07059338
Assets
Linked programs
- Anti-HER2 ADC: Timeline Staleness Signal (3/5)
- Becotatug Vedotin: Low Signal (1/5)
- Chidamide: Timeline Staleness Signal (3/5)
- clarithromycin: Registry Stop Signal (4/5)
- Disitamab Vedotin Injection: Low Signal (0/5)
- Intensity-modulated radiation therapy: Timeline Staleness Signal (4/5)
- SHR-A1811 plus AK112: Low Signal (0/5)
- Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine: Timeline Staleness Signal (2/5)
- Trastuzumab +Cetuximab β+Irinotecan: Low Signal (1/5)